Last €14.38 EUR
Change Today +0.24 / 1.70%
Volume 65.7K
REC On Other Exchanges
REC is not on other exchanges.
As of 8:14 AM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

recordati spa (REC) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/27/15 - €14.40
52 Week Low
01/29/14 - €11.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RECORDATI SPA (REC)

Related News

No related news articles were found.

recordati spa (REC) Related Businessweek News

No Related Businessweek News Found

recordati spa (REC) Details

Recordati S.p.A. is engaged in the research, development, manufacture, marketing, and sale of pharmaceuticals. It offers pharmaceuticals in various therapeutic areas, including cardiovascular, cosmetics, dermatology, dietary supplements, musculo-skeletal disorders and analgesia, pregnancy test, urology, OTC/non-prescription pharmaceuticals, allergy, antiinfectives, central nervous system, endocrinology, gastrointestinal, gynecology, obstetrics, nutrition and related areas, immunosuppressants, pediatrics, pneumology, hematology, oncology, respiratory, analgesia, antipyretics, cold preparations, radio contrast agent, and generics. The company’s flagship product is ZANIDIP (lercanidipine), a calcium-channel blocker for the treatment of hypertension. It also develops Zanipress for the treatment of hypertension; Carbaglu, which is approved in the European Union and is under Phase III clinical trials in the United States for the treatment of organic acidemias; REC 0482 for the treatment of benign prostatic hyperplasia, which is under Phase III clinical trials; and Cystadrops that is under Pre-registration in the European Union for the treatment of ocular cystinosis. In addition, the company develops REC 0438 for the treating overactive bladder in patients with spinal lesions and is under Phase I clinical trials; methadone for treating Cancer related pain and is under Phase IIIb clinical trials; Citrafleet for colonoscopy and is under Phase III clinical trials; and GRASPA for Acute lymphoblastic leukemia and is under Phase II/III clinical trials, as well as for Acute myeloid leukemia and is under Phase II b clinical trials. Further, the company produces pharmaceutical chemicals, such as active ingredients and intermediates for the generic drugs market. Recordati S.p.A has operations in Europe, Australasia, Africa, and the United States. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati S.p.A. is a subsidiary of Fimei S.p.A.

3,961 Employees
Last Reported Date: 03/7/14
Founded in 1926

recordati spa (REC) Top Compensated Officers

Chairman, Chief Executive Officer and General...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2013.

recordati spa (REC) Key Developments

Recordati SpA Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 02:20 PM

Recordati SpA Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 02:20 PM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

Recordati SpA Announces Earnings Results for the Third Quarter Ended September 2014

Recordati SpA announced earnings results for the third quarter ended September 2014. For the quarter, net profit was EUR 41 million, a 31.4% year-on-year increase. EBITDA stood at EUR 71.1 million, up 31.7%, and operating profit totaled EUR 58.6 million, climbing 28%. Revenue grew 4.5% to EUR 234.5 million.

Recordati S.p.A. Resolves to Pay Interim Dividend for the Financial Year 2014

The board of directors of Recordati S.p.A. resolved to distribute an interim dividend relating to the financial year 2014 amounting to EUR 0.26 (before withholding tax) on each outstanding share, excluding shares in treasury stock. The interim dividend will be paid, through the authorized intermediaries, as from November 19, 2014 (record date on November 18, 2014) on coupon No. 14 to be presented on November 17, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REC:IM €14.38 EUR +0.24

REC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €15.38 EUR +0.02
Ipsen SA €44.70 EUR -0.63
Meda AB kr113.90 SEK +0.10
Orion Oyj €29.48 EUR -0.15
Salix Pharmaceuticals Ltd $127.00 USD +1.08
View Industry Companies

Industry Analysis


Industry Average

Valuation REC Industry Range
Price/Earnings 16.8x
Price/Sales 2.6x
Price/Book 3.1x
Price/Cash Flow 16.7x
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECORDATI SPA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at